Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats T-cell acute lymphoblastic leukemia (T-ALL) and … lymphoblastic lymphoma (T-LBL). Sold as Arranon. Every FDA application for this active ingredient: 1 branded and 10 generic.
As of Nov 14, 2026, FDA lists 11 applications for Nelarabine (sold as Arranon), first approved Oct 28, 2005, with 1 new use approved and 0 published complete response letters.
First approved: Oct 28, 2005
Applications: 11
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $130K
First approved in the EU: Aug 22, 2007
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Sandoz
Zydus Pharms
Alembic